Meta-analysis confirms GLP-1 receptor agonists produce a modest but statistically significant reduction in systolic blood pressure across multiple trials.
Modest but significant SBP reductionGLP-1 drugs consistently lowered systolic blood pressure across pooled randomized trial data
What the researchers found
GLP-1 receptor agonists produce a modest but significant reduction in systolic blood pressure, potentially contributing to their cardiovascular protective effects.
Why it matters
High blood pressure is a leading cause of heart disease and stroke. Even small reductions in blood pressure across a large population can prevent many cardiovascular events.
The numbers in context
Comprehensive database search through December 2023. Results reported as mean difference in mmHg using random effects modeling.
How the study worked
Meta-analysis and meta-regression of placebo-controlled randomized controlled trials, using random effects modeling.
Who was studied
Patients with and without diabetes mellitus from placebo-controlled RCTs
What this study cannot tell us
Blood pressure was typically a secondary outcome in the included trials, not the primary focus. The reduction was described as modest.
How to read the evidence
Rated strong: meta-analysis of multiple randomized controlled trials with robust statistical methodology.
When this study was published
Published in 2024 with data through December 2023. Represents the most comprehensive BP analysis for GLP-1 drugs to date.
The bigger picture
High blood pressure is the leading modifiable risk factor for cardiovascular disease. Even small population-level blood pressure reductions can prevent many heart attacks and strokes. GLP-1 drugs' BP effect may be part of their cardiovascular protection.
Questions still open
- How much of GLP-1 drugs' cardiovascular benefit comes from blood pressure reduction vs other mechanisms?
- Does the BP effect vary by specific GLP-1 drug?
Common questions
Do GLP-1 drugs lower blood pressure?
Is the blood pressure effect from weight loss?
Read the original research
Glucagon-like peptide-1 receptor agonists modestly reduced blood pressure among patients with and without diabetes mellitus: A meta-analysis and meta-regression.
Diabetes, obesity & metabolism, 26(6), 2209-2228
Citation
Rivera, Frederick Berro; Lumbang, Grace Nooriza O; Gaid, Danielle Rose Magno; Cruz, Linnaeus Louisse A; Magalong, John Vincent; Bantayan, Nathan Ross B; Lara-Breitinger, Kyla M; Gulati, Martha; Bakris, George. (2024). Glucagon-like peptide-1 receptor agonists modestly reduced blood pressure among patients with and without diabetes mellitus: A meta-analysis and meta-regression.. Diabetes, obesity & metabolism, 26(6), 2209-2228. https://doi.org/10.1111/dom.15529